AbstractIntermittent hypoxia has been used to enhance oxygen delivery in athletes and patients; however, it is unclear whether acute exposure is sufficient to elicit lasting physiologic adaptation(s). The purpose of this study was to evaluate physiologic response(s) to hypobaric‐hypoxic (HH) exercise. Nine participants (4 M/5F; 37.9 ± 12.7 yrs.; 174.3 ± 9.4 cm; 75.3 ± 15.9 kg; 24.4 ± 3.4 kg/m2) were exposed to progressively higher simulated altitudes and completed two HH submaximal exercise sessions (~30 min ea., ≥72 h apart) on a cycle ergometer at the first altitude that posed a significant challenge to them. Altitude was dependent on individual response as determined from heart rate (HR), peripheral oxygenation (SpO2), and the ratio of HR response to SpO2 (HR/SpO2). Statistical analyses included paired samples t‐test (p ≤ 0.05). No significant change in SpO2 (HH‐1: 85 ± 4% vs. HH‐2: 85 ± 4%, p = 0.684) was observed between sessions. However, there were significant decreases in: HR (HH‐1: 150 ± 18 bpm vs. HH‐2: 133 ± 27 bpm, p = 0.001) of 18 bpm (11%); HR/SpO2 (HH‐1: 1.76 ± 0.22 vs. HH‐2: 1.57 ± 0.33, p = 0.012); and RPE (HH‐1: 15 ± 2 vs. HH‐2: 11 ± 4, p = 0.017). While workload significantly increased (HH‐1: 89 ± 36 W vs. HH‐2: 105 ± 36 W, p = 0.024). Some participants had a threshold/challenging altitude, but from a single bout there is evidence of improved tolerance that can last over a week. Further investigation is required to replicate and understand possible mechanisms.
WITHDRAWN: Spatial Analysis of Placentae During Congenital Cytomegalovirus Infection Reveals Distinct Cellular Profiles in Immune Cells and Trophoblasts
Withdrawal Statement The authors have withdrawn the manuscript because the data it contained has been updated. Consequently, they request that this work should not be cited as a reference for any projects to ensure the use of the most current information. For any questions or further clarifications, readers are encouraged to contact the corresponding author directly
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors
Ophthalmic immune-related adverse events (Eye-irAEs) from immune checkpoint inhibitors can cause visual morbidity. The absence of standardized definitions for Eye-irAEs not only impedes the development of evidence-based treatments but also progress in translational research. The objective of this study was to develop consensus guidance for an approach to Eye-irAEs. Four ophthalmic physicians (uveitis specialists and neuro-ophthalmologists) drafted Eye-irAE consensus guidance and definitions, which were reviewed by the multidisciplinary Eye-irAE definition panel. The panel was divided into Group A (Neuro-ophthalmology/Orbital Disease) and Group B (Uveitis/Ocular Surface Disease). A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. For each disorder, five diagnostic components were evaluated: symptoms, examination findings, laboratory studies/imaging findings, diagnostic criteria, and treatment. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free-text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND Corporation/ University of California Los Angeles Health Services Utilization Study (RAND/UCLA) Appropriateness Method with prespecified definitions. 29 panelists from 25 academic medical centers voted on 114 rating scales (66 neuro-ophthalmic/orbital disease components, 48 uveitis/ocular surface disease components); of these, 86.3% (57/66) in Group A and 89.6% (43/48) in Group B reached first-round consensus. After revisions, all items except 6.1% (4/66) in Group A and 1.6% (1/60) in Group B received second-round consensus. Consensus definitions were achieved for 10/11 neuro-ophthalmic/orbital disorders: optic neuritis, inflammatory optic disc edema, arteritic ischemic optic neuropathy, optic perineuritis, orbital inflammation, thyroid eye disease-like orbital inflammation, cavernous sinus syndrome, oculomotor mononeuritis, trochlear mononeuritis, and abducens mononeuritis. Consensus definitions were achieved for 9/10 uveitis/ocular surface disorders: anterior uveitis, intermediate uveitis, posterior uveitis, panuveitis, Vogt-Koyanagi-Harada-like syndrome, sarcoidosis-like syndrome, acute macular neuroretinopathy, dry eye disease, and scleritis. These disease definitions establish a standardized classification for Eye-irAE, highlighting differences between irAEs and other inflammatory disorders. Importantly, diagnostic certainty does not always align directly with the need to treat as an Eye-irAE. Given the consensus from this representative panel group, it is anticipated the definitions will be used broadly across clinical and research settings.
Incidence of Headache in Patients with Right Middle Cerebral Artery Ischemic Stroke Post-Endovascular Therapy: A Retrospective Analysis (P5-12.006)
Background Cancers persist despite expression of immunogenic neoantigens and ongoing antitumor immune responses. While some occult tumors likely are cleared by effective antitumor immune responses, the targeted antigens are not easily identifiable as those tumors spontaneously disappear. Methods We used mouse models with a defined antigenic protein mimicking tumor-specific neoantigens to address the nature of these spontaneous anti-tumor immune responses. Results BALB/c (H-2d ) mice challenged with BALB/c breast tumors expressing the rat-erbB2 oncoprotein succumb to their tumors despite ongoing immune responses targeting tumor-specific model antigens. Meanwhile, congenic BALB.B (H-2b ) and H-2d/H-2b F1 hybrid mice spontaneously eliminate genetically matched tumors in a major histocompatibility complex (MHC)-II dependent manner. Adoptive transfer and immune cell depletion strategies revealed CD4+ T cells and CD20+ B cells are crucial mediators of the protective response in H-2b mice. Furthermore, passive transfer of immune serum from mice rejecting their tumors confers resistance in tumor antigen-tolerant animals with an inversely proportional relationship between tumor outgrowth and the amount of rat-erbB2 specific antibody present in tumor-bearing mice. Introduction of the rat-erb2 ectodomain into other H-2b tumor models also promotes their spontaneous tumor rejection. Notably, the tumor microenvironments differ in rat-erbB2+ tumor-bearing BALB.B and BALB/c mice at the time of fate decision in the models reflecting the differences between effective and ineffective tumor immune responses. Conclusions We find that the effective antitumor immunity targeting neoantigens in these breast cancer models is determined by MHC-II-restricted presentation of optimal cancer-associated antigens. These responses are dependent on CD4+ T cells, B cells, and antigen-specific antibodies.